IPO pricing is expected within 1-2 days of effectiveness. Monitor for the final IPO price and first-day trading performance. The company is a pre-revenue biotech developing cell therapies for Parkinson's disease, making post-IPO cash runway and clinical trial updates key catalysts.
Price Chart
Executive Summary
Aspen Neuroscience's S-1 registration statement for its IPO was declared effective by the SEC on October 29, 2026. The company can now proceed with its initial public offering of 9,375,000 shares of common stock at an expected price range of $15.00 to $17.00 per share, with listing on the Nasdaq Global Select Market under the ticker ASPE.
Key Facts
- EFFECT notice filed October 30, 2026, with effectiveness date of October 29, 2026
- Registration statement on Form S-1 (File No. 333-299393) declared effective
- IPO of 9,375,000 shares of common stock at expected price range of $15.00 to $17.00 per share
- Underwriters granted 30-day option to purchase up to 1,406,250 additional shares
- Listing on Nasdaq Global Select Market under symbol ASPE is contingent upon offering completion
- Lead underwriters: Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel, Oppenheimer & Co.
Financial Impact
IPO expected to raise approximately $140.6M to $159.4M before underwriting discounts and commissions, based on 9,375,000 shares at $15.00-$17.00 per share
Risk Factors
- No prior public market for the stock; price discovery is uncertain
- Pre-revenue biotech with no approved products; high clinical and regulatory risk
- Underwriters' overallotment option could increase dilution by up to 15%
- Market conditions could affect final pricing and demand
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003374 |
| Document: 9999999995-26-003374-index.html | 9999999995-26-003374 |
| Document: 9999999995-26-003374.txt | 9999999995-26-003374 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 1d ago | 424B4 | $14.09 | awaiting T+20 | awaiting T+20 | No price |
Oct 30, 2026 2d ago | EFFECT | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | Press Release | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | 3 | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | 3 | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | 3 | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | 3 | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | 3 | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | 3 | $14.70 | awaiting T+20 | awaiting T+20 | No price |
Oct 29, 2026 2d ago | 3 | $14.70 | awaiting T+20 | awaiting T+20 | No price |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers